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Abstract
Background: Randomised trial protocols may incorporate interim analyses, with the potential to stop the study for
futility if early data show insufficient promise of a treatment benefit. Previously, we have shown that this approach
will theoretically lead to mis-estimation of the treatment effect. We now wished to ascertain the importance of this
phenomenon in practice.
Methods: We reviewed the methods and results in a set of trials that had stopped for futility, identified through an
extensive literature search. We recorded clinical areas, interventions, study design, outcomes, trial setting,
sponsorship, planned and actual treatment effects, sample sizes; power; and if there was a data safety monitoring
board, or a published protocol. We identified: if interim analyses were pre-specified, and how many analyses
actually occurred; what pre-specified criteria might define futility; if a futility analysis formed the basis for stopping;
who made the decision to stop; and the conditional power of each study, i.e. the probability of statistically
significant results if the study were to continue to its complete sample size.
Results: We identified 52 eligible trials, covering many clinical areas. Most trials had multiple centres, tested drugs,
and 40% were industry sponsored. There were 75% where at least one interim analysis was planned a priori; a
majority had only one interim analysis, typically with about half the target total sample size. A majority of trials did
not pre-define a stopping rule, and a variety of reasons were given for stopping. Few studies calculated and
reported low conditional power to justify the early stop. When conditional power could be calculated, it was
typically low, especially under the current trend hypothesis. However, under the original design hypothesis, a few
studies had relatively high conditional power. Data collection often continued after the interim analysis.
Conclusions: Although other factors will typically be involved, we conclude that, from the perspective of
conditional power, stopping early for futility was probably reasonable in most cases, but documentation of the
basis for stopping was often missing or vague. Interpretation of truncated trials would be enhanced by improved
reporting of stopping protocols, and of their actual execution.
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Background
Clinical trial investigators often strive to minimise the
total number of patients who participate in their study,
arrive at a rapid decision about treatment effects, and
lower study costs. Carrying out early analyses of the in-
terim data, with the possibility of stopping the study
early if sufficiently convincing results are found, is there-
fore appealing. A variety of stopping rules have been
proposed for trial protocols when interim analyses are
planned, giving investigators a formal way to evaluate
the interim results, and providing statistical guidance to
decide if the study should indeed be stopped.
One type of rule concerns possible stopping for bene-
fit, if the early data provide strong evidence of an im-
portant treatment effect (usually in favour of the
experimental treatment). Most such rules try to control
overall type I (or α) statistical error rates during a series
of actual or planned interim analyses. Specific stopping
rules can be characterised by their strategy of α-spend-
ing, or equivalently how the decision thresholds on the
magnitude of treatment effect are defined at the time of
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each interim analysis. Some rules use a constant α for all
the interim analyses, while others require stronger statis-
tical significance (by using a smaller α-value) at early
analyses when limited data are available, and corres-
pondingly less stringent criteria (larger α) for later
analyses.
A second type of rule concerns possible stopping for
futility, which may occur when the early data suggest
that an important treatment effect is unlikely to be
found, even if the study were to continue to its full
planned sample size. Investigators may stop the study if
an interim analysis shows little difference between the
experimental and control groups, or even that the con-
trol treatment appears to be superior. In these cases, the
decision about early stopping can be informed by a cal-
culation of conditional power, defined as the probability
of obtaining a statistically significant result if the study is
allowed to continue to its planned completion. Condi-
tional power can be evaluated after making alternative
assumptions about the future data, including two com-
mon choices: i) the current trend observed in the in-
terim data will continue; or ii) the original treatment
effect size proposed in the study design is retained and
still assumed to be correct. Other possibilities are to as-
sume (optimistically) the upper limit of an interim confi-
dence interval for the future treatment effect, for
example at the 80% or 95% confidence level, or (pessim-
istically) to adopt the null hypothesis of no treatment
effect.
In our previous work [1], we developed the theory of
how a futility stopping rule can affect the estimated
treatment effect, together with an illustrative example.
Our results showed that the impact of a stopping rule
depends on several factors, including the true underlying
treatment effect, the magnitude of treatment effect that
the trial is designed to detect, study power, the number
of planned interim analyses, and what assumption is
made about future data to be observed after an interim
analysis. As might be anticipated intuitively, we showed
that if a study actually stops for reasons of futility, its
treatment effect will tend to be under-estimated, pos-
sibly substantially so. Less intuitively, we showed how in
studies with a stopping rule in place, but which do not
actually stop at an interim analysis, there is some over-
estimation of the true effect. Finally, we demonstrated
that there is an overall negative bias in studies with a fu-
tility stopping rule in place. However, because there is
only a small probability of stopping early in many prac-
tical situations, the overall bias is often small, and the
more serious concern is therefore the potential for sub-
stantial under-estimation of the treatment effect in stud-
ies that do actually stop for futility.
From a survey of 894 randomised controlled trial pro-
tocols enrolling patients in the DISCOntinuation of
randomised controlled trials (DISCO) study [2], it was
found that 289 (32%) had pre-specified the possibility of
interim analyses, and 153 (17%) had one or more stop-
ping rules. Specifically, 38 (4.3%) protocols had specified
an interim analysis for futility, and 21 out of these 38
protocols had explicitly specified a statistical stopping
rule. Overall, 46/894 trials (5.1%) were eventually discon-
tinued for early benefit or futility, but 37 of those (80%)
were not stopped based on a formal interim analysis or
stopping rule.
In this paper we describe a systematic survey of the lit-
erature that identified a series of trials that apparently
had stopped early for reasons of futility. We reviewed
the full text of papers reporting these studies, and
reviewed their protocols or trial registry entries if avail-
able, in order to document a variety of their methodo-
logical features, with a focus on aspects of the stopping
rule (if any) and its implementation. Additionally, wher-
ever possible, we calculated the conditional power that
the study had to identify the clinically important treat-
ment effect, as specified at the outset. Our objectives
were to summarise the current practices being used in
the decision to stop a trial for futility, to comment on
the reporting of this aspect of the research, and to assess
the consistency of the conditional power values with the
actual decisions to truncate a study.
Methods
Eligibility criteria and search strategy
We included publications of randomised controlled trials
(RCTs) that (1) investigated superiority of an interven-
tion; (2) reported early stopping of the trial in the title
or abstract; and (3) explicitly reported stopping for futil-
ity in the full text. Hence, we did not consider one-arm
trials, non-inferiority RCTs, or the stopping of individual
trial arms while the remaining trial continued, but
multi-arm trials were admissible. We systematically
searched Medline and Embase using the Ovid interface
for discontinued RCTs published between January 2010
(which was when the Medical Subject Heading Early
Termination of Clinical Trials was introduced) and Au-
gust 2017. The search strategy was designed with the
help of an experienced research librarian (NB) and in-
cluded the Medical Subject Heading and combinations
of text words (see Appendix 1 for our detailed search
strategy). The same search strategy was used previously
for two other meta-epidemiologic studies on discontin-
ued RCTs [3, 4]. We updated the search in August 2017.
Teams of two investigators independently screened ab-
stracts and potentially eligible full texts. They resolved
disagreements about final eligibility by discussion or ar-
bitration with a third investigator (MB). In addition, we
included 18 RCTs stopped for futility that were identi-
fied in a previous retrospective cohort study on the
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prevalence and characteristics of discontinued RCTs (the
DISCO study) [5, 6].
From the full text report of each trial, we recorded
and summarised the essential details of the study
condition and its clinical interventions, the study de-
sign, together with the definition of the main study
outcome and its statistical type. We also noted the
clinical setting, the study sponsorship, if there was a
data safety and monitoring board, if there was a pub-
lished protocol cited or a mentioned trial registration
number; and if CONSORT guidelines were men-
tioned. The anticipated treatment effect on the main
outcome (which we will refer to as the design effect
size), as specified by the investigators, was noted. The
planned and actual total sample sizes, and the study
power as planned at the study outset were obtained.
We identified if interim analyses had been specified a
priori, and, if so, how many such analyses there had
been, with their associated planned and actual sample
sizes. We recorded the criteria for evaluating statis-
tical significance of the treatment effect on the main
study outcome (including 1 vs. 2-sided significance
testing), and any pre-specified criteria for assessing
futility. We determined if a formal futility analysis
was reported, and if it had been the basis for truncat-
ing the study at an interim analysis, or if a different
reason was given. We also noted who made the deci-
sion to stop the trial and if data collection had con-
tinued after the final interim analysis.
Whenever possible, we calculated the conditional
power of the study at the time of stopping, that being
the probability of obtaining a statistically significant re-
sult if the study were to continue to its original, full sam-
ple size. If studies had reported an explicit value of
conditional power themselves, we retained it. For studies
where conditional power was not reported by the
authors, we calculated it ourselves whenever possible,
based on data provided in study reports, and using both
the current trend and design hypotheses. For the
remaining studies, where there was insufficient informa-
tion to calculate conditional power, their claims of futil-
ity could not be explicitly verified.
Conditional power at the kth analysis is defined as the
probability of rejecting the null hypothesis at the com-
pletion of the study, given the data obtained and assum-
ing a hypothesized true treatment θ [7]. If the calculated
value of conditional power falls below a fixed threshold,
early termination for futility is recommended. Threshold
values for conditional power vary depending on the con-
text of the trial, but values in the 0.1 to 0.3 range are
consistent with most common trial designs, and typical
threshold values are in the range of 0.10–0.15 if the ori-
ginally assumed treatment effect is correct [7–9]. We
used 0.15 for the threshold conditional power in our
present calculations. One-sided conditional power at the
kth interim analysis was computed as
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where Ф(.) is the standard normal cumulative distribu-
tion function, cα =Ф
− 1(1-α), Zk is the test statistic calcu-
lated from the observed data at the kth interim analysis,
tk = Ik/IK(0 < tk ≤ tK = 1) represents the proportion of the
total information (often referred to as the “information
time”), and Ik is the information at the kth analysis (k =
1,2, …, K), Ik ¼ SEðθ̂kÞ
−2
[7, 9, 10].
In some cases where a study feature was not reported,
we felt able to make reasonable assumptions as to what
it might be. For instance, some studies did not expli-
citly say they would be testing the treatment effect
against a null value of zero, but such a value seemed
plausible in the context of the other information in the
study report. Some assumed values are noted as such in
our results.
Results
Figure 1 shows how the systematic searches of Medline and
EMBASE, combined with a cohort of RCTs from the
DISCO project, eventually produced our final sample of 52
eligible studies; citations for these studies are provided in
Additional file 4. Additional file 1 gives full details of each
study on the following features: authors; clinical area and
target condition; treatment and control interventions; spon-
sorship (industry or non-industry); if CONSORT guidelines
were mentioned; if a protocol was reported, and if it was in
a journal publication or in a registry only; the study design;
clinical setting and geographic region; if there was a data
safety and monitoring board (DSMB) mentioned; if interim
analyses for futility were planned, and how many; the basis
for a stopping rule, if any; and the actual number of interim
analyses executed. Additional file 2 lists: the planned sam-
ple size; the type I error rate, and if 1- or 2-sided testing
was used; the planned study power; the primary outcome
type; the outcome variable and its null (or control) value;
and the study design hypothesis in terms of expected treat-
ment outcomes or effect sizes. Finally, Additional file 3
gives: the information percent or target sample sizes for
planned interim analyses; the actual information percent at
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the last interim analysis; if there was a reported futility ana-
lysis, or simply a claim of futility; the basis for stopping the
trial, and who made the decision to stop; the main result
(or effect size), with p-values; if conditional power was re-
ported or could be calculated from published details; condi-
tional power values; and if further analyses were executed
after the last planned interim analysis.
Table 1 summarises the distributions of the most im-
portant design characteristics of the sampled trials, in-
cluding administrative details. Most studies used the
parallel group design, and they generally occurred in
multiple trial centres, either nationally or internationally.
While there was a wide variety of clinical settings and
therapeutic areas, a substantial majority (79%) involved a
drug intervention. A placebo type of control was the
most common (60%). About 40% of trials were industry-
sponsored. A majority of trials had a DSMB. Only 19%
of trial reports mentioned CONSORT guidelines. Proto-
cols were available for four (8%) trials only, for an add-
itional 22 (42%) trials we found a trial registry entry, and
for 26 (50%) there was no pre-specified information
available.
Table 2 summarises aspects of the statistical method-
ology, with some emphasis on the stated (as opposed to
actual) approach to potential early stopping for futility.
Binary variables were used most frequently as the pri-
mary study outcome (63%), followed by continuous and
time-to-event outcomes. The inter-quartile range of
planned total sample sizes was from 133 to 586. Setting
aside the four studies whose power could not be deter-
mined, all studies except one had planned power of at
least 80%, and approximately 30% of trials had power ex-
ceeding 90%. This implies that most studies had a con-
ventional (and reasonable) chance of detecting a
Fig. 1 Identification of 52 randomised trials stopped for futility
Table 1 Characteristics of 52 clinical trials that stopped for
futility
Characteristics N
Trial design Parallel/ Factorial/ Cross-over/
Cluster
50/0/0/2




Setting Outpatient/ Inpatient /
Acute care
33/ 11/ 8
Clinical area Oncology 16
Cardiovascular research 9
Mental health 4






Type of intervention Drug/ Surgical procedure/
Other
41/ 3 / 8
Type of control Active intervention/
placebo/ no intervention
14/31/ 7




CONSORT mentioned Yes/No 10/ 42
Published protocol Journal publication/
Trial registry only /
Not reported
4/ 22/ 26
aOther includes: Anaesthesia, nephrology (2), neurology, diabetes care,
musculoskeletal health (2)
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treatment effect, assuming that the treatment effect size
on which the power had been calculated was approxi-
mately correct.
We determined that 73% of the trials had planned
at least one interim analysis for futility. In 6 (12%)
trials, the interim analysis was not planned in ad-
vance, for a variety of reasons, such as: the analysis
was carried out because a majority of patients were
reporting no clinical benefit, despite some apparent
improvement in the primary outcome variable; the
trial’s DSMB requested an interim futility analysis be-
cause of funding difficulties; there was an interim
analysis planned for possible treatment benefit, but
conditional power was also computed to evaluate fu-
tility, because of a low patient recruitment rate; and
the publication of disappointing results in another re-
lated study. In 15% of trials, it was not stated if the
interim analysis was planned or unplanned. The most
common number of planned interim analyses for fu-
tility, when stated, was 1 (45% of trials), but in most
cases it was not clear if further interim analyses
would have been planned after the actual stopping
point of the study. However, in 19% of trials, the
number of planned interim analyses was not pre-
specified.
Table 2 also summarises the stated basis (if any) for
the study’s futility stopping rule. More than half of
the studies (58%) did not formally pre-specify a rule,
guideline, or any other criteria for early stopping.
Nine trials indicated that they would use a threshold
value, either of a suitable test statistic, or as defined
by the observed effect size. Four studies (8%) decided
to use a p-value criterion, while one made a non-
specific statement about potentially using some “futil-
ity” criterion. Only 5 RCT reports (10%) mentioned
that they would consider conditional power. The cri-
terion for one trial was to stop if the event rates in
the two treatment groups showed the experimental to
be doing worse than control.
Over one-third of trials did not state or were unclear
about when their interim analyses would be carried out.
Among those that did pre-specify this feature, about half
of them planned an interim analysis when about 50% of
the target total information would be available. Others
planned an interim analysis as early as 25% or as late as
75%. Two trials planned interim analyses at specific
times, such as annually or after a certain number of
years.
Most trials (77%) had completed only one actual in-
terim analysis before stopping for reasons of futility.
However, there were two cases where, despite stating
that the trial had been abandoned for futility, there was
no actual interim analysis reported at all. The remaining
studies had two or more interim analyses before stop-
ping. About two-thirds of trials proposed to use two-
sided significance tests, 27% with one-sided tests, and
the remainder (8%) being unclear.
Table 3 describes the actual experience of stopping
early for futility. In 58% of studies, the trial was
stopped by the investigators, on advice from the
DSMB to do so. A small number of studies (3, 6%)
were – according to the trial publication - stopped by
the DSMB alone. Many (29%) of studies did not re-
port the decision-making process. The percentage of
information available at the last interim analysis was
quite variable, but as was the case for the planned in-
terim analyses, the most common value was at or
around the half-way point of the study. The earliest
final interim analysis occurred at 11% information (2
studies), and the latest occurred in one study where
the sample size for the interim analysis actually
slightly exceeded the original target for the whole
study. Among the studies where a comparison was
possible, in almost every case the percentage of
Table 2 Statistical design features of 52 clinical trials that stopped for futility
Characteristics N
Type of primary outcome Binary/ Continuous/ time-to-event/ Trinomial 33/ 10/ 8/ 1
Planned sample size Median (IQR) 209 (133–586)
Study power % 70–79 / 80–89 / 90 + / Unclear 1 / 32 / 15 / 4
Interim analyses planned? Yes / No / Not stated 38 / 6 / 8
Number of interim analyses for futility planned 1 / 2 / 3 / Other a / Not stated 19 / 5 / 2 / 3 / 9
Basis for stopping rule Not defined / Threshold / p-value / CP-related / Other 30 / 9 / 4 / 5 / 4
Information % at planned IAb < 40 / 40–59 / 60–79 / Not stated or unclear / Other 7 / 17 / 9 / 19 / 4
Number of actual interim analyses 0 / 1 / 2 / Otherc 2 / 41 / 7 / 2
Type of significance testing One-sided / Two-sided / Unclear 14 / 33 / 5
IA Interim analysis
a: Other includes annual, at least annual, or indefinite
b: Distribution includes studies with stated information % for multiple IAs. “Other” includes studies defined by IAs planned at certain times or with a given number
of patients
c: Other includes one study with 5 IA’s and one study with “annual” IA’s
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information available at the last interim analysis met
the target for planned interim analyses (See Add-
itional file 3 for details).
Various reasons were reported as the basis for stopping
a trial early (Table 3). The most common reasons were
that the desired treatment effect had not been observed,
often with a verbal invocation of futility, in about 40% of
trials. Many investigators indicated their general belief that
the results would not change if the study were to continue,
or that the final results would not be statistically signifi-
cant, but without specifically mentioning the term “futil-
ity”. About 20% of studies stated that a pre-specified
stopping boundary had been crossed, or prior guidelines
were invoked. Other trials gave a variety of verbal sum-
maries of the outcomes, such as stating that “outcomes
did not differ” between treatment groups, that the data
showed “insufficient efficacy”, or that the “intervention
was inferior”. Some trials verbally described their condi-
tional power, that it was “nearly zero”, or implied low con-
ditional power by stating that the study had “almost no
chance” or was “unlikely” to “achieve statistical signifi-
cance”. One RCT claimed that there was an “impossibility
of demonstrating efficacy”, while another described the re-
sults as showing “presumed” futility.
Two-thirds of studies made a claim of futility, but
without providing any statistical details. Four studies
indicated they had carried out a futility analysis, but
did not show its results, while 11 studies gave explicit
values of conditional power. Two of these 11 trials
specified that their conditional power value had been
calculated under an assumption that the current data
trend would continue, while the others did not indi-
cate their underlying assumption about future data.
We were able to calculate conditional power ourselves
for 25 studies, but for the 16 remaining studies, there
was insufficient information available to calculate con-
ditional power.
We examined the distribution of conditional power for
the trials where it could be obtained. Fig. 2 shows the
distributions of conditional power by sponsor, according
to whether it was reported by the investigators or calcu-
lated by us, or by which hypothesis was adopted for its
calculation. Recall that, because an explicit statement of
their assumptions was lacking in almost all studies
where conditional power was reported by the authors,
we treated all 11 of these trials as being under the
current trend hypothesis. Whenever conditional power
had been or could be calculated, it was typically low, es-
pecially under the current trend hypothesis. Fig. 2a indi-
cates that low conditional power (say < 15%) was seen in
most industry and non-industry trials, but there were a
few non-industry trials where the conditional power was
considerably higher.
Among the 25 trials whose conditional power was cal-
culated by us, 23 had conditional power less than 15%
under the current trend assumption (Fig. 2b). Eight of
these trials had conditional power less than 15% under the
original design assumption, 7 trials were in the 15–30%, 4
trials were in the range 30–50%, and 6 trials had relatively
high conditional power (greater than 50%). Among the 11
trials with conditional power reported by investigators, 7
had conditional power less than 15% (one of them indi-
cated that the current trend assumption was adopted, but
the others did not specify what assumption had been
used), two had conditional power larger than 15% (29 and
54%), and the remaining two studies reported their condi-
tional power as less than 30% and less than 60% respect-
ively, but without giving exact results.
Figure 2c shows the distribution of conditional power
for the trials evaluated by us, under both the current
Table 3 Aspects of early stopping of 52 clinical trials that stopped for futility
Characteristics N
Who made decision to stop early Investigators on advice from DSMB / DSMB / Sponsor / Executive committee / Not stated 30 / 3 / 3 / 1 / 15
Actual information % at last IA < 40 / 40–59 / 60–79 / 80+ / Not stated or unclear 11 / 20 / 12 / 6 / 3
Basis for stoppinga Continuation would not change results
Futility mentioned
Lack of treatment effect
Conditional power
Prior guidelines / boundary or threshold crossed









How futility was described Futility claimed, no details
Futility analysis described, but CP not reported
CP reported in detail





Conditional power evaluation Reported by authors / Calculated by us / Impossible to calculate 11 / 25 / 16
Analyses after last IA Yes / No / Unclear or not applicable 21 / 23 / 6 / 2
a: Multiple responses possible
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Fig. 2 a: Distribution of conditional power by study sponsor: current trend assumption b Distribution of reported (11 trials) or calculated (25
trials) conditional power: current trend assumption. c Distribution of conditional power calculated by us (25 trials): current trend and
design assumptions
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trend and original design hypotheses. Not unexpectedly,
conditional power is considerably higher with the design
hypothesis, under which the pre-specified treatment ef-
fect size is retained. Many studies then have conditional
power values which would probably argue in favour of
continuing, based on conventional threshold values of
conditional power (such as 10% or 15%). In contrast, the
current trend hypothesis most often leads to conditional
power values that do not meet such a threshold. From
this comparison, we learn that the decision to stop for
futility depends substantially on what assumption is
made about the expected outcomes in future patients.
Given that all our sampled trials did actually stop for fu-
tility, it appears that the decision may have been made
more frequently on the basis of conditional power under
the current trend model. Recall, however, conditional
power or related ideas were indicated as a major reason
for stopping in only a minority of studies.
There were 44 trials for which we could determine if
additional patients had been included in the final re-
ported analysis, but who had not contributed to the last
interim analysis. In about half of them, data collection
stopped immediately after the interim analysis, but in
the others, patient follow-up and data collection contin-
ued, leading to a larger sample size at the final report. In
one extreme case, the sample size in the final report was
actually slightly larger than the original total target, des-
pite stopping after an interim analysis. This suggests
that, at least in some studies, executing an interim ana-
lysis for futility partially or completely failed in its ob-
jective of reducing its total sample size.
Discussion
This paper has reviewed how interim analyses that led
to an early stop for futility in clinical trials have been re-
ported, in a wide variety of RCTs in the biomedical lit-
erature. Our survey of 52 trial reports showed that, from
the perspective of conditional power, stopping early for
futility was probably a reasonable decision in many
cases, especially if the original design parameters are
abandoned and the current data trend is believed to be
accurate. However, if the design hypothesis is thought to
have enduring credibility, conditional power then would
often not be low enough to satisfy conventional thresh-
olds for stopping the trial early for futility. Hence, the
decision about stopping should necessarily involve some
discussion about what may be expected in future data, if
the trial were to continue.
On the one hand, if investigators believe that outcomes
in future patients are accurately represented by the current
data, and if conditional power is low at the interim analysis,
that would be compatible with a recommendation to stop
early. Relevant here are the findings by Rothwell et al. [11],
who found that the observed effect sizes in a sample of
trials were much smaller than their corresponding target ef-
fect sizes. On the other hand, if investigators feel that the
original design and protocol remain valid, then they might
conclude that the disappointing early results at the interim
analysis are expected to be counterbalanced by more
favourable experience in future patients; and in some of
these cases, conditional power may be sufficiently high to
support a decision to continue the study.
We found that documentation of the stopping rule or
decision-making processes was often missing or vague.
In many cases, it was unclear if the interim analysis had
been planned in advance, or if other interim analyses
might have occurred at a later date. There was often no
pre-specification of how many interim analyses (if any)
had been planned, or when they would take place. Al-
though many trials claimed that futility was the basis for
stopping a trial, there were few details about what spe-
cific criteria (if any) for futility had been applied. Many
studies made only rather general or vague allusions to
the concept of futility, but with no detailed analysis of
the data in this regard. Disappointingly, only a few trials
actually calculated conditional power, which can provide
a more convincing demonstration of futility, or in other
cases can support a decision to continue the study.
However, there were some trial reports where full de-
tails were reported: an example is the study by Powers
et al. [S37], which shows their formal basis for poten-
tially stopping at an interim analysis, the alternative
hypotheses adopted when conditional power was calcu-
lated, the actual conditional power result on which stop-
ping was based, and the fact that a pre-specified (and
described) boundary for futility had been crossed.
Our findings agree closely with those of Avery et al.
[12], whose focus is on internal pilot studies for clinical
trials. They indicate that detailed reporting of the
decision-making for stopping is uncommon, and they
suggest that a pilot stage can provide a good opportunity
to identify futile situations, and thus consider truncating
a study. In related work, Sully et al. [13] simulated a
sample of publicly funded trials in UK, and found that a
single futility analysis with conditional power threshold
of 30% could have correctly stopped 10 / 33 trials which
in fact continued, but which ultimately showed negative
results; such early stops would have saved many un-
necessary patients from being recruited. Sully et al. con-
clude by suggesting that investigators should include
interim analyses for futility in their study design, if pos-
sible. However, there may be a case for continuing the
trial to completion, with the goal of narrowing the confi-
dence interval on the treatment effect sufficiently to rule
out any clinically relevant benefit. In more generality,
CONSORT guidelines for adaptive designs are currently
under development [14], which may lead to improved
reporting practices; however, adequately reporting
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conditional power calculations is not a requirement of
the current guidelines.
Most of the literature on interim analyses in clinical trials
has focused on the inferential properties of early stopping
rules, particularly the maintenance of the overall Type-I
error rate with multiple interim analyses of the data, but
relatively few authors have discussed the impact of early
stopping rules on estimation of the treatment effect. We
have previously [1] used the general theory of conditional
power at the time of an interim analysis, and we were able
to derive analytic expressions for several relevant parame-
ters of interest, including: the mis-estimation of the treat-
ment effect in studies that stop for reasons of futility; (ii)
the estimation of treatment effect in studies that are com-
pleted, but only after an interim analysis that did not lead
to an early stop for futility; (iii) the overall bias in the esti-
mated treatment effect in a study with a futility stopping
rule in its protocol; and (iv) the probability of actually stop-
ping for futility at an interim analysis.
When these expressions were evaluated numerically for
typical trial scenarios, we found that these parameters de-
pend on various factors, including the magnitude of the
underlying treatment effect, the treatment effect that the
trial is designed to detect, planned study power, the num-
ber of planned interim analyses, and what assumptions are
made about future data that might be observed after an
interim analysis. In most practical situations, the probabil-
ity of stopping early is small, and consequently the overall
bias is also often small. Nevertheless, there is the potential
for substantial underestimation of the treatment effect in
studies that do actually stop for futility. We also illustrated
these ideas using data from one clinical trial that did stop
for futility after an interim analysis.
Schou and Marschener [15] have discussed the bias in
estimating the treatment effect with a continuous out-
come variable, calculated relative to the true effect; their
theory pertains to trials with a stopping rule for benefit,
but conditional on not actually stopping the trial. Their
conditional relative bias was found to be approximately
10–20% for adequately powered studies that have one
interim analysis at the halfway point, but it is larger if
the interim analysis occurs later in the study. Schou and
Marschener also consider meta-analyses, where they find
that the inclusion of truncated studies is the preferred
analytic strategy, because it leads to an “essentially un-
biased” estimate of treatment effect.
Hughes et al. [16] showed by simulation that early
stopping can either increase or decrease the strength
of between-study heterogeneity in meta-analyses, and
that this can affect later stages of the analysis. They
indicate that because a single trial with a stopping
rule would yield a biased estimate of the treatment
effect, overviews including such trials would conse-
quently also be biased; however, their numerical
results suggest that the bias would be small as long
as there are a reasonable number of studies available
for the meta-analysis.
There are other concerns about potential bias in esti-
mating the treatment effect in meta-analyses, over and
above the general statistical effects that we considered
in our earlier work. First, if there happens to be an early
truncated trial, it may receive unduly large weight in
any meta-analysis which is executed before other full
studies are completed. This may lead to substantial
mis-estimation of the treatment effect. Elsewhere, we
have presented several real-world examples when such
situations occurred, with negative consequences for pa-
tients [17]. We have also discussed an example of our
meta-analysis of three trials of alternative ventilation
strategies for patients with acute lung injuries; two of
the trials were stopped for futility, and this prevented
us from reaching a definitive conclusion about the pre-
ferred treatment [18].
Second, if the results of a truncated trial are accepted
by the clinical community at face value, there may be a
“freezing” effect, whereby the disappointing results from
the truncated trial make it less likely that confirmatory
studies on the same clinical question will actually take
place. Furthermore, these effects may be accentuated by
the relatively rapid publication of truncated studies (e.g.
by editorial fast tracking of a paper), because of their ap-
parently “definitive” results. We and others have dis-
cussed this issue in more detail elsewhere [1, 19].
While interim analyses are published quite frequently,
under-reporting of this design feature exists, and there-
fore the actual use rate of stopping rules is greater than
it appears in the published literature [2]; a particular
problem is non-reporting of even the existence of a stop-
ping rule for studies that actually complete their target
total sample sizes, without the stopping rule being in-
voked. We acknowledge that there were only four trials
with published protocols in our sample and that we did
not contact trial investigators about unreported details
of potentially existing stopping rules. A further issue is
that a Data Monitoring Committee can over-rule the
findings from an interim analysis, and they may recom-
mend continuation of the study even though the early
results (and the conditional power calculation in particu-
lar) are disappointing. Also, note that our survey in-
cluded studies where the final sample size was larger
than the sample size at the last interim analysis; again,
the fact that an interim analysis had taken place may not
be evident from the final study report for some studies.
Conclusions
Although other factors will typically be involved in the
decision to terminate a trial early, we conclude that,
from the perspective of conditional power, stopping
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early for futility was probably reasonable in most of the
trials we reviewed, as long as the interim data are repre-
sentative of future data, if the study were to continue. In
contrast, if one takes the position that the original design
hypothesis, including the target effect size, are still valid,
then conditional power may sometimes provide reason-
able support for the trial to continue. However, docu-
mentation of the basis for stopping in our sample of
trials was often missing or vague. Conditional power was
not commonly calculated, and even in studies where it
was calculated, the crucial assumptions concerning fu-
ture data were often not specified.
Literature suggests that the inclusion of a stopping
rule in a study protocol introduces the possibility of
mis-estimation and/or bias in the treatment effect.
Specifically, trials that do stop early for reasons of ap-
parent futility will tend to under-estimate the under-
lying treatment effect; and studies with a protocol that
specifies interim analyses, but which actually continue
until the target total sample size is achieved, will be
subject to overall bias in the estimated treatment ef-
fect. Accordingly, we believe it is important for trial
reports to provide details of their plans for interim
analyses. Reported estimates of treatment effects are
more difficult to interpret if investigators fail to report
aspects of their study design, such as if interim ana-
lyses (and how many) had been planned, when they
would be executed, and what criteria would be applied
to decide about stopping.
When studies do stop early, it is particularly important
to know what the criteria had been applied for declaring
futility, including what assumptions were made about fu-
ture data, as these assumptions would importantly affect
the value of conditional power, for example. If studies fail
to provide the details of their interim analysis protocols, it
becomes difficult to assess the impact of these aspects of
the study design on their reported treatment effects. Inter-
pretability of the results of truncated trials would be
greatly enhanced by improved reporting of stopping rule
protocols, and of their execution in practice.
The expected mis-estimation or bias in the treatment ef-
fect associated with futility stopping rules cannot easily be
computed, because these quantities are functions of the
true (and hence unknown) treatment effect itself. Never-
theless, general theory and simulation work can inform us
about the general patterns of mis-estimation and bias to
be anticipated for various typical scenarios [1]. Awareness
of these tendencies should be helpful to investigators in
the interpretation of trial results. At the very least, ad-
equate reporting of interim analysis and stopping rule pro-
tocols should alert users of these results that trials that
stop early for futility will yield under-estimates of treat-
ment effects, possibly quite seriously.
In summary, our main findings are as follows:
 Many studies are unclear about if or when interim
analyses would take place, and criteria for early
stopping for futility are frequently not pre-specified.
 Many studies that stop early make general claims of
futility, but without any formal analysis.
 The decision to stop for futility depends
substantially on what assumption is made about the
expected outcomes in future patients. The few
studies that report conditional power calculations
often do not state the critical assumption about
expected outcomes in future data.
 Conditional power was typically low under the current
trend assumption; however, under the original design
hypothesis, the conditional power value would
sometimes support continuation of the trial.
 Interpretation of trial results is made difficult by
incomplete reporting of the plans for and execution
of interim analyses for futility.
Based on these findings, we make the following
recommendations:
 Pre-specified plans for interim analyses of futility
should be reported; essential details include the
number and timing of interim analyses, and criteria
for declaring futility and stopping the trial.
 Conditional power should be calculated and
reported at interim analyses, to support the decision
to stop or continue a trial.
 The crucial assumption concerning the expected
pattern of future data, on which basis conditional
power is calculated, should be clearly stated and
defended. Common choices are to assume that the
current trend in the data will continue, or that the
original design hypothesis will be retained.
 Investigators should be aware: 1) that trials that
have stopped early for futility will generally under-
estimate the treatment effect, possibly substantially;
2) that studies with a futility stopping rule, but
which continue to completion will tend to over-
estimate treatment benefit; and 3) that the inclusion
of interim analyses for futility in a trial protocol will
imply negative bias (over all studies, stopped or not)
in the estimated treatment effect.
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